The early innings of the obesity landscape is starting to take shape, and it seems to be forming similar patterns...
Read NowModular Medical (MODD) announced the 510(k) submission of their MODD1 insulin pump to the FDA last week. On average, the FDA takes approximately...
PremiumResearch - The 100% move from GW Pharmaceuticals (GWPH) on Monday is a good opportunity to circle back on another mid-cap epilepsy player that’s down 40% year-to-date and 60% from its highs last year.
PremiumInsights - Shares of GW Pharmaceuticals (GWPH) doubled on Monday with the much-anticipated release of positive data from a phase 3 study of Epidiolex, the company’s proprietary formulation of … Continue Reading
Read nowResearch - It’s been some time since we’ve revisited Synergy Pharmaceuticals (SGYP). The company continues to guide for phase 3 plecanatide IBS-C data in the first half … Continue Reading
PremiumResearch - UniQure (QURE) has essentially traded sideways since the company presented the first results from their ongoing open-label study of hemophilia gene therapy AMT-060 in January.
Read nowInsights - Biotech had a Super Wednesday after Bernie Sanders’ not-so-super Tuesday.
PremiumResearch - Rockwell Medical (RMTI) reported fourth quarter and full-year 2015 results after the bell this evening. The accompanying conference call was bizarre, and the stock is … Continue Reading
Read nowResearch - Chimerix (CMRX) said in a conference call this morning that they now expect results from AdVise, which we wrote about last week, this spring.
Premium
